摘要
目的观察丹参酮ⅡA对慢性乙型肝炎肝纤维化的临床疗效。方法将确诊的60例患者随机分为两组:治疗组30例用丹参酮ⅡA+贺普丁的治疗方案,对照组30例用贺普丁的治疗方案,观察治疗前后两组患者肝功能和血清肝纤维化指标的变化。结果治疗组肝功能和肝纤维化指标明显改善,且与治疗前或对照组比较差异显著(P<0.05)。结论丹参酮ⅡA可有改善慢性乙型肝炎肝纤维化患者的临床症状及肝功能。
Objective To observe the clinical effect of tanshinone ⅡA in treating hepatic fibrosis in chronic hepatitis B（CHB）. Methods Sixty patients with CHB were randomly divided into two groups：treatment group was treated with tanshinone ⅡA and heptedin,the patients in the control group took heptodin. Before and after treatment, the serum fibrosis marks and liver function were detected in all the patients. Resuits The serum fibrosis marks and liver function in the treatment group were significantly improved compared with those before treatment, with significant difference between them（P〈 0.05 ）. Conclusion Tanshinone ⅡA has a significant effect to improve liver function and can correct the mark of hepatic fibrosis.
出处
《中国现代医生》
2009年第25期73-74,共2页
China Modern Doctor
